Targeting Mutations in Advanced Melanoma.
作者信息
Phadke Manali S, Smalley Keiran S M
机构信息
Department of Tumor Biology, Moffitt Cancer Center & Research Institute, Tampa, FL.
Department of Cutaneous Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL.
出版信息
J Clin Oncol. 2023 May 10;41(14):2661-2664. doi: 10.1200/JCO.23.00205. Epub 2023 Mar 22.
Abstract
摘要
相似文献
1
Targeting Mutations in Advanced Melanoma.针对晚期黑色素瘤中的突变
J Clin Oncol. 2023 May 10;41(14):2661-2664. doi: 10.1200/JCO.23.00205. Epub 2023 Mar 22.
2
Evaluation of two different mutations in codon 12 of NRAS gene in ulcerated penile mucosal nodular malignant melanoma pT4b of the 90-year-old man in perspective of targeted therapy of NRAS-mutated advanced melanomas.从NRAS突变的晚期黑色素瘤靶向治疗角度评估一名90岁男性阴茎溃疡性黏膜结节性恶性黑色素瘤pT4b中NRAS基因第12密码子的两种不同突变
Dermatol Ther. 2020 Nov;33(6):e14115. doi: 10.1111/dth.14115. Epub 2020 Sep 4.
3
BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.俄罗斯黑色素瘤患者的BRAF和NRAS突变：一项全国性研究的结果
Melanoma Res. 2016 Oct;26(5):442-7. doi: 10.1097/CMR.0000000000000278.
4
BRAF N581S and NRAS Q61R-mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors.BRAF N581S和NRAS Q61R突变的恶性黑色素瘤以及对BRAF/MEK抑制剂的敏感性。
J Dermatol. 2023 Jan;50(1):e28-e29. doi: 10.1111/1346-8138.16592. Epub 2022 Oct 11.
5
[Gene abnormalities in melanoma and signal transduction antagonists].[黑色素瘤中的基因异常与信号转导拮抗剂]
Gan To Kagaku Ryoho. 2013 Apr;40(4):453-7.
6
Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil.BRAF和NRAS原发性皮肤黑色素瘤的皮肤镜特征：与点状分布及蓝白色薄纱样表现的关联
J Eur Acad Dermatol Venereol. 2020 Feb;34(2):e57-e59. doi: 10.1111/jdv.15906. Epub 2019 Sep 11.
7
BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.前瞻性原发性皮肤黑色素瘤系列研究中的BRAF、NRAS和MC1R状态
Br J Dermatol. 2015 Apr;172(4):1128-31. doi: 10.1111/bjd.13521. Epub 2015 Mar 6.
8
The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.一项基于临床的转移性黑色素瘤队列中 BRAF 和 NRAS 突变的临床意义。
Br J Dermatol. 2013 Nov;169(5):1049-55. doi: 10.1111/bjd.12504.
9
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.BRAF 和 NRAS 基因突变状态与转移性黑色素瘤的预后、远处转移部位和化疗反应的相关性。
Br J Cancer. 2014 Jul 15;111(2):292-9. doi: 10.1038/bjc.2014.287. Epub 2014 Jun 10.
10
Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort.基于临床的转移性黑色素瘤队列中BRAF/NRAS同时突变的临床意义
Br J Dermatol. 2020 May;182(5):1281-1283. doi: 10.1111/bjd.18641. Epub 2019 Dec 2.
引用本文的文献
1
NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1 Mutant Melanoma.NF1缺失促进EGFR激活并使NF1突变型黑色素瘤对EGFR抑制敏感。
Cancer Res. 2025 Jun 10. doi: 10.1158/0008-5472.CAN-24-3904.
2
Clinicopathological Features of Non-Small Cell Lung Carcinoma with NRAS Mutation.具有NRAS突变的非小细胞肺癌的临床病理特征
J Pers Med. 2025 May 16;15(5):199. doi: 10.3390/jpm15050199.
3
Recurrent Melanoma in a Patient with Chronic Lymphocytic Leukemia (CLL) Presenting with an Apparent Co-Existing NRAS and BRAF Mutation: A Diagnostic and Treatment Conundrum.一名慢性淋巴细胞白血病（CLL）患者出现复发性黑色素瘤，同时存在明显的NRAS和BRAF共突变：诊断与治疗难题。
Int J Mol Sci. 2025 Jan 25;26(3):1029. doi: 10.3390/ijms26031029.
4
Dynamic Multilevel Regulation of EGFR, KRAS, and MYC Oncogenes: Driving Cancer Cell Proliferation Through (Epi)Genetic and Post-Transcriptional/Translational Pathways.表皮生长因子受体（EGFR）、KRAS和MYC癌基因的动态多级调控：通过（表观）遗传及转录后/翻译途径驱动癌细胞增殖
Cancers (Basel). 2025 Jan 14;17(2):248. doi: 10.3390/cancers17020248.
5
The Olive Oil Monophenolic Secoiridoid Ligstroside Aglycone Suppresses Melanoma Progression by Targeting the BRAF Signaling Pathway.橄榄油单酚类裂环环烯醚萜橄榄苦苷元通过靶向BRAF信号通路抑制黑色素瘤进展。
Molecules. 2025 Jan 1;30(1):139. doi: 10.3390/molecules30010139.
6
Atypical Exon 2/3 Mutants G48C, Q43K, and E37K Present Oncogenic Phenotypes Distinct from Characterized NRAS Variants.非典型外显子 2/3 突变 G48C、Q43K 和 E37K 表现出与典型 NRAS 变异体不同的致癌表型。
Cells. 2024 Oct 12;13(20):1691. doi: 10.3390/cells13201691.
本文引用的文献
1
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.NAPORAFENIB 联合曲美替尼治疗 - 突变型黑色素瘤的初步疗效证据：一项 Ib 期、开放标签研究扩展臂的结果。
J Clin Oncol. 2023 May 10;41(14):2651-2660. doi: 10.1200/JCO.22.02018. Epub 2023 Mar 22.
2
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.达拉非尼联合曲美替尼对比纳武利尤单抗联合伊匹木单抗治疗晚期-突变型黑色素瘤患者：DREAMseq 试验-ECOG-ACRIN EA6134。
J Clin Oncol. 2023 Jan 10;41(2):186-197. doi: 10.1200/JCO.22.01763. Epub 2022 Sep 27.
3
Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation.NRAS 突变体能增强黑色素瘤起始过程中的 BRAF 结合。
Nat Commun. 2022 Jun 7;13(1):3153. doi: 10.1038/s41467-022-30881-9.
4
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.Ribociclib 联合 Binimetinib 治疗NRAS 突变型黑色素瘤患者的 Ib/II 期临床试验。
Clin Cancer Res. 2022 Jul 15;28(14):3002-3010. doi: 10.1158/1078-0432.CCR-21-3872.
5
NRAS mutant melanoma: Towards better therapies.NRAS 突变型黑色素瘤：迈向更好的治疗方法。
Cancer Treat Rev. 2021 Sep;99:102238. doi: 10.1016/j.ctrv.2021.102238. Epub 2021 May 29.
6
Sotorasib for Lung Cancers with p.G12C Mutation.索托拉西布治疗 p.G12C 突变型肺癌。
N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4.
7
Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.抗 PD-1 治疗后给予靶向治疗通过持续的抗肿瘤免疫导致小鼠黑色素瘤模型中的持久应答。
Cancer Immunol Res. 2021 May;9(5):554-567. doi: 10.1158/2326-6066.CIR-20-0905. Epub 2021 Mar 2.
8
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.LXH254，一种强效和选择性的 ARAF spared BRAF 和 CRAF 抑制剂，用于治疗 MAPK 驱动的肿瘤。
Clin Cancer Res. 2021 Apr 1;27(7):2061-2073. doi: 10.1158/1078-0432.CCR-20-2563. Epub 2020 Dec 22.
9
KRAS Inhibition with Sotorasib in Advanced Solid Tumors.索托拉西布治疗晚期实体瘤的 KRAS 抑制作用。
N Engl J Med. 2020 Sep 24;383(13):1207-1217. doi: 10.1056/NEJMoa1917239. Epub 2020 Sep 20.
10
E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.E2F 报告揭示了 MEK1/2-CDK4/6 靶向和 mTOR-S6 耐药机制的有效方案。
Cancer Discov. 2018 May;8(5):568-581. doi: 10.1158/2159-8290.CD-17-0699. Epub 2018 Mar 1.
Zotero 插件